Recent efforts have focused on designing Tmz derivatives to bypass either MGMT or MMR‐mediated resistance in GBM cells.[7, 8] These approaches use mechanism‐based drug design to synthesize analogues of Tmz that result in inducing unique lesions on DNA that are either not repaired by MGMT or not dependent on MMR status. The gene discussed is MGMT; the disease is glioblastoma.